Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America..
The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:213 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 213(2016), 7 vom: 01. Apr., Seite 1124-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dowall, Stuart David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 26.07.2016 Date Revised 24.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiv565 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM256004536 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM256004536 | ||
| 003 | DE-627 | ||
| 005 | 20231224175709.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiv565 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0853.xml |
| 035 | |a (DE-627)NLM256004536 | ||
| 035 | |a (NLM)26715676 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dowall, Stuart David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2016 | ||
| 500 | |a Date Revised 24.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Ebola | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a neutralization | |
| 650 | 4 | |a therapeutic | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Glycoproteins |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 700 | 1 | |a Callan, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Zeltina, Antra |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Abdulla, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Strecker, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Fehling, Sarah K |e verfasserin |4 aut | |
| 700 | 1 | |a Krähling, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Bosworth, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Charlton, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Landon, John |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Hewson, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Nasidi, Abdulsalami |e verfasserin |4 aut | |
| 700 | 1 | |a Bowden, Thomas A |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Miles W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 213(2016), 7 vom: 01. Apr., Seite 1124-33 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:213 |g year:2016 |g number:7 |g day:01 |g month:04 |g pages:1124-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiv565 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 213 |j 2016 |e 7 |b 01 |c 04 |h 1124-33 | ||